Lipocine Inc (NASDAQ:LPCN) fell 11.2% during trading on Monday . The stock traded as low as $1.55 and last traded at $1.66. 686,752 shares were traded during trading, a decline of 6% from the average session volume of 733,922 shares. The stock had previously closed at $1.87.
Several brokerages recently commented on LPCN. HC Wainwright reiterated a “buy” rating and set a $3.00 target price on shares of Lipocine in a report on Monday, March 11th. LADENBURG THALM/SH SH reiterated a “buy” rating on shares of Lipocine in a report on Thursday, January 17th. Finally, ValuEngine upgraded Lipocine from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd.
The firm has a market cap of $39.64 million, a P/E ratio of -3.25 and a beta of 0.73. The company has a debt-to-equity ratio of 0.73, a current ratio of 4.63 and a quick ratio of 4.63.
Lipocine (NASDAQ:LPCN) last announced its earnings results on Wednesday, March 6th. The specialty pharmaceutical company reported ($0.15) EPS for the quarter, missing the consensus estimate of ($0.13) by ($0.02). Analysts expect that Lipocine Inc will post -0.84 EPS for the current year.
A number of hedge funds have recently bought and sold shares of LPCN. JPMorgan Chase & Co. increased its holdings in Lipocine by 145.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 95,429 shares of the specialty pharmaceutical company’s stock worth $132,000 after purchasing an additional 56,606 shares during the last quarter. Vanguard Group Inc. increased its holdings in Lipocine by 4.9% during the 3rd quarter. Vanguard Group Inc. now owns 747,984 shares of the specialty pharmaceutical company’s stock worth $1,032,000 after purchasing an additional 35,000 shares during the last quarter. Vanguard Group Inc increased its holdings in Lipocine by 4.9% during the 3rd quarter. Vanguard Group Inc now owns 747,984 shares of the specialty pharmaceutical company’s stock worth $1,032,000 after purchasing an additional 35,000 shares during the last quarter. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in Lipocine during the 1st quarter worth approximately $256,000. Institutional investors own 8.83% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This article was reported by Fairfield Current and is the sole property of of Fairfield Current. If you are viewing this article on another domain, it was copied illegally and reposted in violation of international copyright and trademark law. The correct version of this article can be accessed at https://www.fairfieldcurrent.com/news/2019/04/17/lipocine-lpcn-trading-down-11-2.html.
Lipocine Company Profile (NASDAQ:LPCN)
Lipocine Inc, a specialty pharmaceutical company, focuses on the development of pharmaceutical products in the area of men's and women's health. Its primary development programs are based on oral delivery solutions for poorly bioavailable drugs. The company has a portfolio of product candidates designed to produce pharmacokinetic characteristics and facilitate lower dosing requirements, bypass first-pass metabolism in certain cases, reduce side effects, and eliminate gastrointestinal interactions that limit bioavailability.
Read More: Compound Interest
Receive News & Ratings for Lipocine Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lipocine and related companies with MarketBeat.com's FREE daily email newsletter.